Company intelligence / Profile preview

Zonk Drug R&D

Guangzhou, Guangdong, Chinaechemi.com ↗

Ownership: Private
Development stage: Other

Overview

The company has completed pre-clinical studies for Binaprofen, a non-steroidal anti-inflammatory drug, which is in the registration stage with China's SFDA. Felbinac Trometamol targeting COXs is in Phase 2 clinical trials. The company also reports initial evaluation of new antineoplastic agents ("COPEN") and has applied for multiple patents including international PCT applications.

Therapeutic areas: GastroenterologyCardiovascularOncologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Dalian Tianyu Pharmaceutical Co., Ltd.

Beyond the preview

Go deeper on Zonk Drug R&D.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zonk Drug R&D.

Explore the full profile